Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Deborah J L Wong

Title(s)HS Associate Clinical Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Aug 14; 31(16):3400-3411. Harrington KJ, Champiat S, Brody JD, Cho BC, Romano E, Golan T, Hyngstrom JR, Strauss J, Oh DY, Popovtzer A, Gomez-Roca C, Perets R, Kim SB, Wong DJ, Powell SF, Khilnani A, Jemielita T, Zhao Q, Zhao R, Ingham M. PMID: 40499147.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    2. Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment. JNCI Cancer Spectr. 2025 Jul 01; 9(4). Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian PA, Kerr RP, Lee JK, Nabili V, Sercarz JA, Suh JD, Wang MB, Wong DJ, Chai-Ho W, Jafarvand MG, Bahri S, Jank E, Reddy VK, Steinberg ML, Chin RK, Savjani RR. PMID: 40700605; PMCID: PMC12349773.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. JAMA. 2025 05 13; 333(18):1599-1607. Haddad R, Fayette J, Teixeira M, Prabhash K, Mesia R, Kawecki A, Dechaphunkul A, Dinis J, Guo Y, Masuda M, Hsieh CY, Ghi MG, Vaz de Melo Sette C, Harrington K, Tahara M, Saba NF, Lau A, Jiang T, Yan Y, Ballinger M, Kaul M, Matheny C, Cuchelkar V, Wong DJ. PMID: 40079944; PMCID: PMC11907359.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    4. Multidisciplinary Care for Anaplastic Thyroid Cancer-End-of-Life Care as a Standard of Care. Laryngoscope. 2025 Sep; 135(9):3444-3451. Chen H, Evans L, Schaaff C, Labib M, Oh E, Ashendouek M, Sajed D, Ho WC, Wong DJ, Martin EJ, St John M. PMID: 40342186; PMCID: PMC12353459.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    5. Patient-reported quality of life and adherence outcomes after integrating exclusive liquid meal replacement in patients with head and neck cancer undergoing chemoradiation: results from a phase II study. Front Oncol. 2024; 14:1433503. Valle LF, Chu FI, Wang X, Erman A, Hernandez J, Kaoh E, Edgar N, Raldow AC, Wong DJ, Steinberg ML, Kishan AU, Chin RK, Hegde JV. PMID: 39839777; PMCID: PMC11747389.
      View in: PubMed   Mentions:
    6. A Case of Posterior Reversible Encephalopathy Syndrome Associated With Pembrolizumab and Cetuximab Combination Therapy. Cureus. 2024 Oct; 16(10):e71867. Patel N, Karanth R, Isaacs DJ, Cohen J, Wong DJ, Delshad SD. PMID: 39559603; PMCID: PMC11573227.
      View in: PubMed   Mentions:
    7. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol. 2025 Jan; 92(1):68-77. Hughes BGM, Guminski A, Bowyer S, Migden MR, Schmults CD, Khushalani NI, Chang ALS, Grob JJ, Lewis KD, Ansstas G, Day F, Ladwa R, Stein BN, Muñoz Couselo E, Meier F, Hauschild A, Schadendorf D, Basset-Seguin N, Modi B, Dalac-Rat S, Dunn LA, Flatz L, Mortier L, Guégan S, Heinzerling LM, Mehnert JM, Trabelsi S, Soria-Rivas A, Stratigos AJ, Ulrich C, Wong DJ, Beylot-Barry M, Bossi P, Bugés Sánchez C, Chandra S, Robert C, Russell JS, Silk AW, Booth J, Yoo SY, Seebach F, Lowy I, Fury MG, Rischin D. PMID: 39245360.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    8. Therapeutic Advances in Advanced Basal Cell Carcinoma. Cancers (Basel). 2024 Sep 04; 16(17). Alkassis S, Shatta M, Wong DJ. PMID: 39272933; PMCID: PMC11394629.
      View in: PubMed   Mentions: 2  
    9. Improved Survival of Advanced-Stage Anaplastic Thyroid Cancer With Systemic Therapy. Laryngoscope. 2025 Jan; 135(1):478-484. Evans LK, Chen H, Taki Labib M, Cronkite DA, Yu AC, Ashendouek M, Elashoff D, Chai-Ho W, Wong DJ, St John M. PMID: 39162326; PMCID: PMC11635144.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    10. A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma. Clin Cancer Res. 2023 11 14; 29(22):4555-4563. Hanna GJ, Ahn MJ, Muzaffar J, Keam B, Bowles DW, Wong DJ, Ho AL, Kim SB, Worden F, Yun T, Meng X, Van Tornout JM, Conlan MG, Kang H. PMID: 37643133; PMCID: PMC10643996.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    11. High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial. Int J Radiat Oncol Biol Phys. 2023 10 01; 117(2):348-354. Ma TM, Wong DJ, Chai-Ho W, Mendelsohn A, St John M, Abemayor E, Chhetri D, Sajed D, Dang A, Chu FI, Xiang M, Savjanji R, Weidhaas J, Steinberg ML, Cao M, Kishan AU, Chin RK. PMID: 37141981.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    12. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 03; 615(7953):697-704. Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, Purandare B, An D, Quach BB, Nguyen D, Xia H, Jilani S, Shao K, McHugh C, Greer J, Peabody P, Nayak S, Hoover J, Said S, Jacoby K, Dalmas O, Foy SP, Conroy A, Yi MC, Shieh C, Lu W, Heeringa K, Ma Y, Chizari S, Pilling MJ, Ting M, Tunuguntla R, Sandoval S, Moot R, Hunter T, Zhao S, Saco JD, Perez-Garcilazo I, Medina E, Vega-Crespo A, Baselga-Carretero I, Abril-Rodriguez G, Cherry G, Wong DJ, Hundal J, Chmielowski B, Speiser DE, Bethune MT, Bao XR, Gros A, Griffith OL, Griffith M, Heath JR, Franzusoff A, Mandl SJ, Ribas A. PMID: 36890230; PMCID: PMC10441586.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    13. A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance. Clin Cancer Res. 2023 03 01; 29(5):888-898. Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M. PMID: 36342102.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    14. Impact of early detection on cancer curability: A modified Delphi panel study. PLoS One. 2022; 17(12):e0279227. Schwartzberg L, Broder MS, Ailawadhi S, Beltran H, Blakely LJ, Budd GT, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk BJ, Wong DJ, Campos C, Yermilov I. PMID: 36542647; PMCID: PMC9770338.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    15. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas. J Clin Med. 2022 Dec 07; 11(24). Kirtane K, St John M, Fuentes-Bayne H, Patel SP, Mardiros A, Xu H, Ng EW, Go WY, Wong DJ, Sunwoo JB, Welch JS. PMID: 36555876; PMCID: PMC9781632.
      View in: PubMed   Mentions: 4  
    16. Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report. J Immunother Cancer. 2022 Oct; 10(10). Kroloff MJ, Holz JB, Stern O, Shepherd CJ, Morrow M, Kayitalire L, Wong DJ. PMID: 36202556; PMCID: PMC9540849.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166. Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. PMID: 34965944; PMCID: PMC9365346.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    18. Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor. Future Oncol. 2022 Apr; 18(11):1333-1342. Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. PMID: 35144482; PMCID: PMC9066292.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    19. Implementing a Tailored Psychosocial Distress Screening Protocol in a Head and Neck Cancer Program. Laryngoscope. 2022 08; 132(8):1600-1608. Brauer ER, Lazaro S, Williams CL, Rapkin DA, Madnick AB, Dafter R, Cheng G, Porter A, Abemayor E, Chai-Ho W, Morasso E, Erman A, Chhetri D, St John M, Wong DJ. PMID: 34953151; PMCID: PMC9875715.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    20. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Curr Oncol. 2021 12 20; 28(6):5466-5479. Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. PMID: 34940094; PMCID: PMC8700717.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    21. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2021 10; 9(10). Guigay J, Lee KW, Patel MR, Daste A, Wong DJ, Goel S, Gordon MS, Gutierrez M, Balmanoukian A, Le Tourneau C, Mita A, Vansteene D, Keilholz U, Schöffski P, Grote HJ, Zhou D, Bajars M, Penel N. PMID: 34663640; PMCID: PMC8524383.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    23. Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial. Clin Lung Cancer. 2022 05; 23(3):273-281. Wong DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, Zhu J, Zhang X, Cha E. PMID: 34456145.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    24. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021 06; 22(6):883-892. Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, Chai-Ho W, Oppelt P, Ghosh D, Bykowski J, Molinolo A, Pittman E, Estrada MV, Gold K, Daniels G, Lippman SM, Natsuhara A, Messer K, Cohen EEW. PMID: 33989559; PMCID: PMC12140401.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCTClinical Trials
    25. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408. Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. PMID: 33709428; PMCID: PMC8251721.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    26. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021 06 10; 39(17):1856-1864. Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, Wong DJ, Ahn MJ, Boni V, Even C, Fayette J, Flor MJ, Harrington K, Kim SB, Licitra L, Nixon I, Saba NF, Hackenberg S, Specenier P, Worden F, Balsara B, Leoni M, Martell B, Scholz C, Gualberto A. PMID: 33750196; PMCID: PMC8189627.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    27. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC). Invest New Drugs. 2021 02; 39(1):182-192. Hecht JR, Papadopoulos KP, Falchook GS, Patel MR, Infante JR, Aljumaily R, Wong DJ, Autio KA, Wainberg ZA, Bauer TM, Javle M, Pant S, Bendell J, Hung A, Ratti N, VanVlasselaer P, Verma R, Leveque J, Rao S, Oft M, Naing A. PMID: 32910338; PMCID: PMC8944136.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    28. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. Cancer. 2020 09 01; 126(17):3972-3981. Hanna GJ, Guenette JP, Chau NG, Sayehli CM, Wilhelm C, Metcalf R, Wong DJ, Brose M, Razaq M, Pérez-Ruiz E, Cohen EEW, Aggarwal R, Scholz C, Gualberto A, Ho AL. PMID: 32557577; PMCID: PMC8266417.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    29. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 02; 21(2):294-305. Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. PMID: 31952975; PMCID: PMC7771329.
      View in: PubMed   Mentions: 199     Fields:    Translation:HumansCTClinical Trials
    30. Addition of Chemotherapy Is Associated With Decreased Survival in Early-Stage (T1-2N0M0) Glottic Squamous Cell Carcinoma Treated With Definitive Radiotherapy. JCO Precis Oncol. 2019 Dec; 3:1-14. Wang C, Kishan AU, Raldow A, Beron P, Wong DJ, St John M, Steinberg ML, Chin R. PMID: 35100668.
      View in: PubMed   Mentions: 1     Fields:    
    31. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 2019 11; 20(11):1544-1555. Naing A, Wong DJ, Infante JR, Korn WM, Aljumaily R, Papadopoulos KP, Autio KA, Pant S, Bauer TM, Drakaki A, Daver NG, Hung A, Ratti N, McCauley S, Van Vlasselaer P, Verma R, Ferry D, Oft M, Diab A, Garon EB, Tannir NM. PMID: 31563517; PMCID: PMC8436252.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCTClinical Trials
    32. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell. 2018 11 12; 34(5):775-791.e3. Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PMID: 30423297; PMCID: PMC8098754.
      View in: PubMed   Mentions: 132     Fields:    Translation:HumansAnimalsCells
    33. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018 10 22; 6(1):111. Le Tourneau C, Hoimes C, Zarwan C, Wong DJ, Bauer S, Claus R, Wermke M, Hariharan S, von Heydebreck A, Kasturi V, Chand V, Gulley JL. PMID: 30348224; PMCID: PMC6198369.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansCTClinical Trials
    34. SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study. Cancer Discov. 2018 10; 8(10):1250-1257. Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ, Barve M, Daniels GA, Wong DJ, Schmidt EV, Candia AF, Coffman RL, Leung ACF, Janssen RS. PMID: 30154193; PMCID: PMC6719557.
      View in: PubMed   Mentions: 171     Fields:    Translation:HumansCTClinical Trials
    35. Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress. Cancer Cell. 2018 05 14; 33(5):890-904.e5. Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, Braas D, Grasso CS, Palaskas N, Ribas A, Graeber TG. PMID: 29657129; PMCID: PMC5953834.
      View in: PubMed   Mentions: 486     Fields:    Translation:HumansCells
    36. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. Cancer. 2018 05 01; 124(9):2010-2017. Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I, Gulley JL. PMID: 29469949; PMCID: PMC5947549.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    37. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815. Atkins MB, Hodi FS, Thompson JA, McDermott DF, Hwu WJ, Lawrence DP, Dawson NA, Wong DJ, Bhatia S, James M, Jain L, Robey S, Shu X, Homet Moreno B, Perini RF, Choueiri TK, Ribas A. PMID: 29358500.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    38. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discov. 2018 02; 8(2):184-195. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT. PMID: 29247021.
      View in: PubMed   Mentions: 204     Fields:    Translation:HumansCTClinical Trials
    39. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15; 123(24):4800-4807. Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. PMID: 29125624; PMCID: PMC6263029.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    40. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck. Otolaryngol Clin North Am. 2017 Aug; 50(4):775-782. Shetty AV, Wong DJ. PMID: 28755705.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    41. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017 05; 18(5):599-610. Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, Leach J, Edenfield WJ, Wang D, Grote HJ, Heydebreck AV, Chin K, Cuillerot JM, Kelly K. PMID: 28373005; PMCID: PMC5522719.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansCTClinical Trials
    42. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569. Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. PMID: 27528724; PMCID: PMC5657013.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCTClinical Trials
    43. Targeted Therapy for Melanoma. Cancer Treat Res. 2016; 167:251-62. Wong DJ, Ribas A. PMID: 26601866.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    44. Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. Case Rep Oncol Med. 2015; 2015:893694. Warner WA, Wong DJ, Palma-Diaz F, Shibuya TY, Momand J. PMID: 26634163; PMCID: PMC4655020.
      View in: PubMed   Mentions: 3  
    45. Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2015 Jul 02; 14:128. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 26134498; PMCID: PMC4488977.
      View in: PubMed   Mentions: 4     Fields:    
    46. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer. 2015 Feb 03; 14:27. Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. PMID: 25645078; PMCID: PMC4320814.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    47. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates. Ann Transl Med. 2014 Dec; 2(12):122. Wong DJ, Hurvitz SA. PMID: 25568875; PMCID: PMC4260046.
      View in: PubMed   Mentions: 28  
    48. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer. 2014 Aug 20; 13:194. Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. PMID: 25142146; PMCID: PMC4155088.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    49. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014 Jul 01; 20(13):3446-57. Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. PMID: 24812408; PMCID: PMC4079734.
      View in: PubMed   Mentions: 207     Fields:    Translation:HumansCells
    50. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol Cancer. 2014 Apr 16; 13:83. Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. PMID: 24735930; PMCID: PMC4021505.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    51. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374; PMCID: PMC4070853.
      View in: PubMed   Mentions: 135     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    52. Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res. 2014 May; 2(5):459-68. Wong DJ, Rao A, Avramis E, Matsunaga DR, Komatsubara KM, Atefi MS, Escuin-Ordinas H, Chodon T, Koya RC, Ribas A, Comin-Anduix B. PMID: 24795358; PMCID: PMC4010948.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    53. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol Cancer. 2012 Apr 19; 11:22. von Euw E, Atefi M, Attar N, Chu C, Zachariah S, Burgess BL, Mok S, Ng C, Wong DJ, Chmielowski B, Lichter DI, Koya RC, McCannel TA, Izmailova E, Ribas A. PMID: 22515704; PMCID: PMC3444881.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    Deborah's Networks
    Concepts (226)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (73)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California